Bally’s Corporation (NYSE: BALY) eyes evoke plc (LSE: EVOK): why a William Hill deal would reshape UK gambling
Why SK Life Science Labs’ AACR 2026 data could put targeted protein degradation back in the oncology spotlight
Read More Pharma Industry News ESTEVE acquires Caprelsa from Sanofi to boost rare cancer drug portfolio and global specialty focus ESTEVE is acquiring Caprelsa® from Sanofi to expand its rare cancer drug portfolio. The deal boosts ESTEVE's focus on highly specialized treatments. byPallavi MadhirajuJuly 2, 2025